Yang Zhi, Zuo Quan, Liu Rong, Wu Hui, Chen Jia, Xiong Li, Jia Jieqi, Xiang Zhibi
Department of Oncology, People's Hospital of Xiangxi Tujia and Miao Autonomous Prefecture, First Affiliated Hospital of Jishou University, Jishou, Hunan, China.
Department of Otolaryngology, People's Hospital of Xiangxi Tujia and Miao Autonomous Prefecture, First Affiliated Hospital of Jishou University, Jishou, Hunan, China.
Front Oncol. 2024 Oct 10;14:1465038. doi: 10.3389/fonc.2024.1465038. eCollection 2024.
This retrospective study aimed to explore the efficiency and untoward reaction of liposomal paclitaxel versus docetaxel for locally advanced nasopharyngeal carcinoma (NPC).
This retrospective study included 115 patients diagnosed with NPC at our hospital between January 2018 and December 2021. Patients were stratified into two groups based on their treatment with either liposomal paclitaxel ( = 71) or docetaxel ( = 44) as part of the neoadjuvant chemotherapy regimen. Objective response rate (ORR), progression-free survival (PFS), locoregional relapse-free survival (LRFS), distant metastasis-free survival (DMFS), and overall survival (OS) were compared between the two groups.
ORR was significantly improved in the liposomal paclitaxel group than in the docetaxel group (62.0% versus 40.9%, = 0.028). The 3-year PFS (PFS: 84.4% versus 77.5%, = 0.303), LRFS (95.8% versus 94.4%, = 0.810), DMFS (87.2% versus 83.0%, = 0.443), and OS (90.7% versus 88.8%, = 0.306) revealed no significance. The neutrophil-to-lymphocyte ratio [hazard ratio (HR): 3.510; = 0.039] and distant metastasis (HR: 4.384; = 0.035) were regarded as the risk factors using multivariate regression analysis. Moreover, the incidence of leukopenia at grades 1-2 in the liposomal paclitaxel group was significantly lower than that in the docetaxel group (28.1% versus 79.5%, < 0.05).
Liposomal paclitaxel had better efficacy in terms of short-term effects and lower incidence of leukopenia at grades 1-2 compared with the docetaxel group.
本回顾性研究旨在探讨脂质体紫杉醇与多西他赛治疗局部晚期鼻咽癌（NPC）的疗效和不良反应。
本回顾性研究纳入了2018年1月至2021年12月期间在我院确诊为NPC的115例患者。根据患者接受脂质体紫杉醇（n = 71）或多西他赛（n = 44）作为新辅助化疗方案的一部分进行分层分组。比较两组的客观缓解率（ORR）、无进展生存期（PFS）、局部区域无复发生存期（LRFS）、远处转移无复发生存期（DMFS）和总生存期（OS）。
脂质体紫杉醇组的ORR显著高于多西他赛组（62.0%对40.9%，P = 0.028）。3年PFS（PFS：84.4%对77.5%，P = 0.303）、LRFS（95.8%对94.4%，P = 0.810）、DMFS（87.2%对83.0%，P = 0.443）和OS（90.7%对88.8%，P = 0.306）无显著差异。多因素回归分析显示中性粒细胞与淋巴细胞比值[风险比（HR）：3.510；P = 0.039]和远处转移（HR：4.384；P = 0.035）为危险因素。此外，脂质体紫杉醇组1 - 2级白细胞减少的发生率显著低于多西他赛组（28.1%对79.5%，P < 0.05）。
与多西他赛组相比，脂质体紫杉醇在短期疗效方面更好，且1 - 2级白细胞减少的发生率更低。
